| Melanie S Nehls, LPN | |
|
158 Sycamore Rd, Harpers Ferry, WV 25425-5083 | |
| (304) 261-1241 | |
| Not Available |
| Full Name | Melanie S Nehls |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 158 Sycamore Rd, Harpers Ferry, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629260708 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LP40932 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Melanie S Nehls, LPN 158 Sycamore Rd, Harpers Ferry, WV 25425-5083 Ph: (304) 261-1241 | Melanie S Nehls, LPN 158 Sycamore Rd, Harpers Ferry, WV 25425-5083 Ph: (304) 261-1241 |
News Archive
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has been awarded a Qualifying Therapeutic Discovery Project grant (QTDP) from the U.S. Government. The grant, in the amount of $244,479, has been made to defer some of the Company's research expenditures related to the development of its novel and patented technology, CollaFix™, as a drug delivery device.
Researchers have found that genetic variation may increase susceptibility of some astronauts to develop higher-than-normal carbon dioxide levels in the blood, which may contribute to eye abnormalities, including grooved bands on the retina in the eye and swelling of the optic nerve.
SeraCare Life Sciences, Inc. today announced that the Company has launched a set of new products in its diagnostic controls and panels portfolio—the SeraCare HIV-1 Seroconversion Panels. Each of the six panels consists of a set of undiluted plasma samples from a single plasma donor collected over a period of time during the development of detectable specific antibodies to HIV in the blood, or seroconversion, and is highly characterized with enhanced product information.
Provident Healthcare Ventures, LLC is pleased to announce the launch of its inaugural Principals Fund I with $25 million of committed capital. All capital invested in the Fund will be provided by the principals of Provident, affirming their belief that providing early-stage healthcare services companies with crucial resources, such as capital and operating expertise, will significantly increase enterprise value over the life of the investment.
› Verified 5 days ago